
|Videos|February 11, 2022
Dr. Dason on selecting neoadjuvant or adjuvant therapy for patients with UTUC
Author(s)Urology Times staff
“We definitely don't have a clear standard,” says Shawn Dason, MD, FRCSC.
Advertisement
In this video, Shawn Dason, MD, FRCSC, discusses the factors that urologists should consider when counseling patients with upper tract urothelial carcinoma about neoadjuvant and adjuvant treatment options. These insights stem from a study that was presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference. Dason is a urologic oncologist and an assistant professor of urology at The Ohio State University in Columbus.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
2
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care
5










